Document information 09/02/2010 21:00
Current documents
SPC 3757
PIL 3208
Total: 6965
Submissions in the last 3 months
Updated: 1118
New: 264

2010 Medicines Compendium


 

What's New

These are the latest new, updated and retired (removed) Summaries of Product Characteristics (SPCs) and Patient Information Leaflets (PILs) on the eMC website. More help.

Filter Results

Document Type:
PIL SPC
Status:  
New Update Retired
09 February 2010
New 1, Updated 13, Retired 0, [Total 14]
Active Ingredients / Generics: nefopam hydrochloride
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 8 - MARKETING AUTHORISATION NUMBER(S)
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: apomorphine hydrochloride
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 8 - MARKETING AUTHORISATION NUMBER(S)
Active Ingredients / Generics: ibandronic sodium monohydrate
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 5.2 - Pharmacokinetic Properties
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 10 date of revision of the text
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: diclofenac sodium
  • Improved Electronic Presentation
Active Ingredients / Generics: vinflunine ditartrate
  • New SPC for new product
Active Ingredients / Generics: gadopentetic acid (dimeglumine salt)
  • Change to section 5.3 - Preclinical Safety Data
Active Ingredients / Generics: xylometazoline hydrochloride
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: xylometazoline hydrochloride
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: lenalidomide
  • Change to information for healthcare professionals
  • Change to warnings or special precautions for use
Active Ingredients / Generics: potassium chloride
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 5.3 - Preclinical Safety Data
Active Ingredients / Generics: fosamprenavir calcium
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change due to harmonisation of SPC
08 February 2010
New 0, Updated 13, Retired 0, [Total 13]
Active Ingredients / Generics: budesonide
  • Change to Further Information section
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 5.2 - Pharmacokinetic Properties
Active Ingredients / Generics: theophylline
  • Change to MA holder contact details
Active Ingredients / Generics: ethinylestradiol, etonogestrel
  • Improved Electronic Presentation
Active Ingredients / Generics: pimozide
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to side-effects
Active Ingredients / Generics: xylometazoline hydrochloride
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: xylometazoline hydrochloride
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: fosphenytoin sodium
  • Change to appearance of the medicine
  • Change to Further Information section
  • Change to date of revision, Correction of spelling/typing errors
  • Change to warnings or special precautions for use
Active Ingredients / Generics: strontium ranelate
  • Change to section 4.8 - Undesirable Effects
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: pivmecillinam hydrochloride
  • Change to date of revision
  • Change to name of manufacturer
Active Ingredients / Generics: paroxetine hydrochloride hemihydrate
  • Change of manufacturer
  • Change to warnings or special precautions for use
  • Change to side-effects
Active Ingredients / Generics: verapamil hydrochloride
  • Change to warnings or special precautions for use
  • Change to side-effects
Active Ingredients / Generics: nelfinavir mesilate
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 5.2 - Pharmacokinetic Properties
05 February 2010
New 2, Updated 31, Retired 2, [Total 35]
PIL retired Alli 60mg hard capsules
Active Ingredients / Generics: orlistat
  • PIL Retired pending re-submission
Active Ingredients / Generics: apomorphine hydrochloride
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 8 - MARKETING AUTHORISATION NUMBER(S)
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 8 - MARKETING AUTHORISATION NUMBER(S)
Active Ingredients / Generics: capsaicin
  • Change to section 4.8 - Undesirable Effects
Active Ingredients / Generics: hyoscine butylbromide
  • New PIL for new product
Active Ingredients / Generics: cisplatin
  • Change to information for healthcare professionals
  • Change to date of revision
  • Change to warnings or special precautions for use
Active Ingredients / Generics: potassium clavulanate, amoxicillin sodium
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 8 - MARKETING AUTHORISATION NUMBER(S)
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: potassium clavulanate, amoxicillin sodium
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 8 - MARKETING AUTHORISATION NUMBER(S)
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: hydrochlorothiazide, irbesartan
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Active Ingredients / Generics: macrogol 4000
  • New PIL for new product
  • Change to section 6. 3 - Shelf Life
Active Ingredients / Generics: ethosuximide
  • Change to section 6.2 - Incompatibilities
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: ethosuximide
  • Change to section 6.2 - Incompatibilities
  • Change to section 10 date of revision of the text
Active Ingredients / Generics: diclofenac sodium
  • Improved Electronic Presentation
  • Change to date of revision
  • Changes to therapeutic indications
  • Change due to harmonisation of PIL.
  • Change to date of revision
  • Change due to harmonisation of PIL.
  • Change to date of revision
Active Ingredients / Generics: fosaprepitant dimeglumine
  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.1 - Pharmacodynamic Properties
Active Ingredients / Generics: fosaprepitant dimeglumine
  • Change to side-effects
Active Ingredients / Generics: triamcinolone acetonide
  • Change to date of revision
Active Ingredients / Generics: omeprazole
  • Improved Electronic Presentation
Active Ingredients / Generics: naltrexone hydrochloride
  • Change to packaging
  • Change to date of revision
  • Change to storage instructions
Active Ingredients / Generics: pegfilgrastim
  • Change to date of revision
Active Ingredients / Generics: ethinylestradiol, levonorgestrel
  • Change of trade or generic name
  • Change to date of revision
Active Ingredients / Generics: testosterone undecanoate
  • Improved Electronic Presentation
Active Ingredients / Generics: methylphenidate hydrochloride
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.7 - Effects on Ability to Drive and Use Machines
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 5.3 - Preclinical Safety Data
  • Change to section 6. 3 - Shelf Life
Active Ingredients / Generics: paroxetine hydrochloride hemihydrate
  • Change to warnings or special precautions for use
  • Change to side-effects
PIL retired Strong Co-danthramer capsules
Active Ingredients / Generics: poloxamer 188, dantron
  • PIL Submitted in error
Active Ingredients / Generics: testosterone
  • Improved Electronic Presentation
Active Ingredients / Generics: bosentan monohydrate
  • Change to section 4.8 - Undesirable Effects
Active Ingredients / Generics: bosentan monohydrate
  • Change to section 4.8 - Undesirable Effects
  • Change due to harmonisation of SPC


© 2010 Datapharm Communications Ltd

Go to www.medicines.org.uk